Research Explorer

Project

Understanding and exploiting glycosylation in immunotherapy.
Code
01GA1817
Duration
01 January 2017 → 31 October 2021
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Natural sciences
    • Biochemistry and metabolism not elsewhere classified
    • Microbiology not elsewhere classified
  • Medical and health sciences
    • Immunology not elsewhere classified
    • Medical biochemistry and metabolism not elsewhere classified
    • Microbiology not elsewhere classified
    • Immunology not elsewhere classified
    • Medical biochemistry and metabolism not elsewhere classified
    • Microbiology not elsewhere classified
    • Immunology not elsewhere classified
    • Medical biochemistry and metabolism not elsewhere classified
    • Microbiology not elsewhere classified
  • Engineering and technology
    • Biomaterials engineering not elsewhere classified
    • Biological system engineering not elsewhere classified
    • Biomaterials engineering not elsewhere classified
    • Biomechanical engineering not elsewehere classified
    • Other (bio)medical engineering not elsewhere classified
    • Environmental engineering and biotechnology not elsewhere classified
    • Industrial biotechnology not elsewhere classified
    • Other biotechnology, bio-engineering and biosystem engineering not elsewhere classified
  • Agricultural and food sciences
    • Veterinary medicine not elsewhere classified
Keywords
vaccines glycosylation pathway engineering
 
Project description
 

Many vaccine proteins are extensively modified with sugars (glycans), but it has been difficult until recently to produce pure glycoforms of such vaccine proteins. This has obstructed the targeted engineering of the sugar structures for studying and improving vaccine efficacy. New biotechnology being developed at Ghent University overcomes this research bottleneck, which may lead to new vaccines for allergy, flu and worm infections.